Minireview: functional roles of tissue kallikrein, kinins, and kallikrein-related peptidases in lung cancer.
KLKs
Kallikrein-related peptidases
Kinin receptors
Kinins
Lung cancer
SARS-CoV-2
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
05 Jul 2023
05 Jul 2023
Historique:
received:
17
01
2023
accepted:
17
06
2023
medline:
7
7
2023
pubmed:
5
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
Despite campaigns and improvements in detection and treatment, lung cancer continues to increase worldwide and represents a major public health problem. One approach to treating patients suffering from lung cancer is to target surface receptors overexpressed on tumor cells, such as GPCR-family kinin receptors, and proteases that control tumor progression, such as kallikrein-related peptidases (KLKs). These proteases have been visualized in recent years due to their contribution to the progression of cancers, such as prostate and ovarian cancer, facilitating the invasive and metastatic capacity of tumor cells in these tissues. In fact, KLK3 is the specific prostate antigen, the only tissue-specific biomarker used to diagnose this malignancy. In lung cancer to date, evidence indicates that KLK5, KLK6, KLK8, KLK11, and KLK14 are the major peptidases regulated and involved in its progression. The expression levels of KLKs in this neoplasm are modulated by the secretome of the different cell types present in the tumor microenvironment, the cancer subtype and the tumor stage, among others. Considering the multiple functions of kinin receptors and KLKs, this review highlights their roles, even considering the SARS-CoV-2 effects. Since lung cancer is often diagnosed in advanced stages, our efforts should focus on early diagnosis, validating for example specific KLKs, especially in high-risk populations such as smokers and people exposed to carcinogenic fumes, oil fields, and contaminated workplaces, unexplored fields to investigate. Furthermore, their modulation could be considered as a promising approach in lung cancer therapeutics.
Identifiants
pubmed: 37405520
doi: 10.1007/s12032-023-02090-x
pii: 10.1007/s12032-023-02090-x
doi:
Substances chimiques
Tissue Kallikreins
EC 3.4.21.35
Kallikreins
EC 3.4.21.-
Kinins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
224Subventions
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 1201635
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 1221415
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 1201378
Organisme : Agencia Nacional de Investigación y Desarrollo
ID : 21201493
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660 .
doi: 10.3322/caac.21660
pubmed: 33538338
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535–54. https://doi.org/10.1016/S0140-6736(21)00312-3 .
doi: 10.1016/S0140-6736(21)00312-3
pubmed: 34273294
Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and molecular classification of lung cancer. Cancer Treat Res. 2016. https://doi.org/10.1007/978-3-319-40389-2 .
doi: 10.1007/978-3-319-40389-2
pubmed: 27535388
Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021;22:8661. https://doi.org/10.3390/ijms22168661 .
doi: 10.3390/ijms22168661
pubmed: 34445366
pmcid: 8395394
Knight SB, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7:170070. https://doi.org/10.1098/rsob.170070 .
doi: 10.1098/rsob.170070
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345–56. https://doi.org/10.1038/s41591-021-01450-2 .
doi: 10.1038/s41591-021-01450-2
pubmed: 34385702
Neth P, Arnhold M, Nitschko H, Fink E. The mRNAs of prekallikrein, factors XI and XII, and kininogen, components of the contact phase cascade are differentially expressed in multiple non-hepatic human tissues. Thromb Haemost. 2001;85:1043–7. https://doi.org/10.1055/s-0037-1615961 .
doi: 10.1055/s-0037-1615961
pubmed: 11434682
Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Phamacological Rev. 1992;44:1–80.
Marceau F. Kinin B1 receptors: a review. Immunopharmacology. 1995;30:1–26. https://doi.org/10.1016/0162-3109(95)00011-H .
doi: 10.1016/0162-3109(95)00011-H
pubmed: 7591710
Abraham WM, Scuri M, Farmer SG. Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease. Eur J Pharmacol. 2006;533:215–21. https://doi.org/10.1016/j.ejphar.2005.12.071 .
doi: 10.1016/j.ejphar.2005.12.071
pubmed: 16455073
Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, Prindle T, Fulton WB, Wang S, et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol. 2018;314:L17-31. https://doi.org/10.1152/ajplung.00498.2016 .
doi: 10.1152/ajplung.00498.2016
pubmed: 28935640
Rampa DR, Murugesan P, Chao H, Feng H, Dai W, Lee D, et al. Reversal of pulmonary arterial hypertension and neointimal formation by kinin B1 receptor blockade. Respir Res BioMed Central. 2021;22:1–16. https://doi.org/10.1186/s12931-021-01875-w .
doi: 10.1186/s12931-021-01875-w
Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab. 2000;11:54–60. https://doi.org/10.1016/S1043-2760(99)00225-8 .
doi: 10.1016/S1043-2760(99)00225-8
pubmed: 10675891
Charlesworth MC, Young CYF, Miller VM, Tindall DJ. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl. 1999;20:220–9.
pubmed: 10232657
Kryza T, Lalmanach G, Lavergne M, Lecaille F, Reverdiau P, Courty Y, et al. Pro-angiogenic effect of human kallikrein-related peptidase 12 (KLK12) in lung endothelial cells does not depend on kinin-mediated activation of B2 receptor. Biol Chem. 2013;394:385–91. https://doi.org/10.1515/hsz-2012-0291 .
doi: 10.1515/hsz-2012-0291
pubmed: 23152405
Matus CE, Ehrenfeld P, Figueroa CD. The family of kallikrein-related peptidases and kinin peptides as modulators of epidermal homeostasis. Am J Physiol Cell Physiol. 2022;323:C1070–87. https://doi.org/10.1152/ajpcell.00012.2022 .
doi: 10.1152/ajpcell.00012.2022
pubmed: 35993513
Mella C, Figueroa CD, Otth C, Ehrenfeld P. Involvement of kallikrein-related peptidases in nervous system disorders. Front Cell Neurosci. 2020. https://doi.org/10.3389/fncel.2020.00166 .
doi: 10.3389/fncel.2020.00166
pubmed: 32848618
pmcid: 7405910
Filippou PS, Karagiannis GS, Musrap N, Diamandis EP. Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. Crit Rev Clin Lab Sci. 2016;53:277–91. https://doi.org/10.3109/10408363.2016.1154643 .
doi: 10.3109/10408363.2016.1154643
pubmed: 26886390
Cereda V, Formica V, Menghi A, Pellicori S, Roselli M. Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges. Expert Opin Investig Drugs. 2015;24:929–47. https://doi.org/10.1517/13543784.2015.1035708 .
doi: 10.1517/13543784.2015.1035708
pubmed: 25858813
Sotiropoulou G, Pampalakis G. Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci Elsevier Ltd. 2012;33:623–34. https://doi.org/10.1016/j.tips.2012.09.005 .
doi: 10.1016/j.tips.2012.09.005
Kryza T, Silva ML, Loessner D, Heuzé-Vourch N, Clements JA. The kallikrein-related peptidase family: dysregulation and functions during cancer progression. Biochimie. 2016;122:283–99. https://doi.org/10.1016/j.biochi.2015.09.002 .
doi: 10.1016/j.biochi.2015.09.002
pubmed: 26343558
Morizane S, Yamasaki K, Kabigting FD, Gallo RL. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D3, and retinoic acid. J Invest Dermatol. 2010;130:1297–306. https://doi.org/10.1038/jid.2009.435.Kallikrein .
doi: 10.1038/jid.2009.435.Kallikrein
pubmed: 20090765
pmcid: 2908513
Sheng L, Anderson PH, Turner AG, Pishas KI, Dhatrak DJ, Gill PG, et al. Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016;164:90–7. https://doi.org/10.1016/j.jsbmb.2015.10.012 .
doi: 10.1016/j.jsbmb.2015.10.012
pubmed: 26485663
Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, et al. Dual targeting of the androgen receptor and hypoxia-inducible factor 1a pathways synergistically inhibits castration-resistant prostate cancer cells. Mol Pharmacol. 2015;87:1006–12. https://doi.org/10.1124/mol.114.097477 .
doi: 10.1124/mol.114.097477
pubmed: 25829060
pmcid: 4429716
Figueroa CD, Molina L, Bhoola KD, Ehrenfeld P. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer. Biol Chem. 2018;399:937–57. https://doi.org/10.1515/hsz-2018-0111 .
doi: 10.1515/hsz-2018-0111
pubmed: 29885274
Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human Kallikrein-related peptidases. J Biol Chem. 2009;284:32989–94. https://doi.org/10.1074/jbc.R109.027946 .
doi: 10.1074/jbc.R109.027946
pubmed: 19819870
pmcid: 2785139
Srinivasan S, Kryza T, Batra J, Clements J. Remodelling of the tumour microenvironment by the kallikrein-related peptidases. Nat Rev Cancer. 2022;22:223–38. https://doi.org/10.1038/s41568-021-00436-z .
doi: 10.1038/s41568-021-00436-z
pubmed: 35102281
Even-Ram S, Beatrice U, Patrizia C, Sorina G-G, Miriam M, Yoav G, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998;4:909–14. https://doi.org/10.1038/nm0898-909 .
doi: 10.1038/nm0898-909
pubmed: 9701242
Hollenberg MD, Oikonomopoulou K, Hansen KK, Saifeddine M, Ramachandran R, Diamandis EP. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol Chem. 2008;389:643–51. https://doi.org/10.1515/BC.2008.077 .
doi: 10.1515/BC.2008.077
pubmed: 18627296
Ehrenfeld P, Manso L, Pavicic MF, Matus CE, Borquez C, Lizama A, et al. Bioregulation of kallikrein-related peptidases 6, 10 and 11 by the Kinin b1 receptor in breast cancer cells. Anticancer Res. 2014;34:6925–38.
pubmed: 25503118
Christiansen SC, Proud D, Cochrane CG. Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects. J Clin Invest. 1987;79:188–97. https://doi.org/10.1172/JCI112782 .
doi: 10.1172/JCI112782
pubmed: 3540008
pmcid: 424020
Poblete MT, Garces G, Figueroa CD, Bhoola KD. Localization of immunoreactive tissue kallikrein in the seromucous glands of the human and guinea-pig respiratory tree. Histochem J. 1993;25:834–9. https://doi.org/10.1007/BF02388115 .
doi: 10.1007/BF02388115
pubmed: 8300405
Proud D, Vio CP. Localization of immunoreactive tissue kallikrein in human trachea. Am J Respir Cell Mol Biol. 1993;8:16–9. https://doi.org/10.1165/ajrcmb/8.1.16 .
doi: 10.1165/ajrcmb/8.1.16
pubmed: 8417752
Singh J, Naran A, Misso NL, Rigby PJ, Thompson PJ, Bhoola KD. Expression of kallikrein-related peptidases (KRP/hK5, 7, 6, 8) in subtypes of human lung carcinoma. Int Immunopharmacol. 2008;8:300–6. https://doi.org/10.1016/j.intimp.2007.08.015 .
doi: 10.1016/j.intimp.2007.08.015
pubmed: 18182244
Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP. Cellular distribution of human tissue kallikreins: immunohistochemical localization. Biol Chem. 2006;387:653–63. https://doi.org/10.1515/BC.2006.084 .
doi: 10.1515/BC.2006.084
pubmed: 16800726
McCarthy CG, Wilczynski S, Wenceslau CF, Webb RC. A new storm on the horizon in COVID-19: bradykinin-induced vascular complications. Vascul Pharmacol. 2021;137:106826. https://doi.org/10.1016/j.vph.2020.106826 .
doi: 10.1016/j.vph.2020.106826
pubmed: 33358968
pmcid: 7834250
Colarusso C, Terlizzi M, Pinto A, Sorrentino R. A lesson from a saboteur: high-MW kininogen impact in coronavirus-induced disease 2019. Br J Pharmacol. 2020;177:4866–72. https://doi.org/10.1111/bph.15154 .
doi: 10.1111/bph.15154
pubmed: 32497257
pmcid: 7300552
da Silva MF, de Araújo-Júnior JX, da Silva-Júnior EF, Heimfarth L, Martins-Filho PR, de Souza Siqueira QJ, et al. Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives. Naunyn Schmiedebergs Arch Pharmacol. 2022;395:275–83. https://doi.org/10.1007/s00210-022-02206-6 .
doi: 10.1007/s00210-022-02206-6
pubmed: 35089406
pmcid: 8795307
Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Iraj N. COVID-19 cytokine storm: the anger of inflammation. Cytokine. 2020;133:1–10. https://doi.org/10.1016/j.cyto.2020.155151 .
doi: 10.1016/j.cyto.2020.155151
Nagashima S, Dutra AA, Arantes MP, Zeni RC, Klein CK, de Oliveira FC, et al. COVID-19 and lung mast cells: the kallikrein-kinin activation pathway. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23031714 .
doi: 10.3390/ijms23031714
pubmed: 36430210
pmcid: 9696576
Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020;9:1–16. https://doi.org/10.7554/eLife.59177 .
doi: 10.7554/eLife.59177
Rex DAB, Vaid N, Deepak K, Dagamajalu S, Prasad TSK. A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases. Mol Biol Rep. 2022;49:9915–27. https://doi.org/10.1007/s11033-022-07539-2 .
doi: 10.1007/s11033-022-07539-2
pubmed: 35596055
pmcid: 9122735
van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JWM, de Mast Q, Brüggemann RJ, et al. Kallikrein-kinin blockade in patients with covid-19 to prevent acute respiratory distress syndrome. Elife. 2020;9:1–9. https://doi.org/10.7554/ELIFE.57555 .
doi: 10.7554/ELIFE.57555
Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B, et al. Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fl uid of patients with severe COVID-19. EBioMedicine. 2022;83:1–13. https://doi.org/10.1016/j.ebiom.2022.104195 .
doi: 10.1016/j.ebiom.2022.104195
Trifilieff A, Lach E, Dumont P, Gies J. Bradykinin binding sites in healthy and carcinomatous human lung. Br J Pharmacol. 1994;111:1228–32. https://doi.org/10.1111/j.1476-5381.1994.tb14876.x .
doi: 10.1111/j.1476-5381.1994.tb14876.x
pubmed: 8032609
pmcid: 1910127
Mak JCW, Barnes PJ. Autoradiographic visualization of bradykinin receptors in human and guinea pig lung. Eur J Pharmacol. 1991;194:37–43. https://doi.org/10.1016/0014-2999(91)90121-6 .
doi: 10.1016/0014-2999(91)90121-6
pubmed: 1647963
Chee J, Naran A, Misso NL, Thompson PJ, Bhoola KD. Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol Chem. 2008;389:1225–33. https://doi.org/10.1515/BC.2008.139 .
doi: 10.1515/BC.2008.139
pubmed: 18713009
Wong J, Sia YY, Misso NL, Aggarwal S, Ng A, Bhoola KD. Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura. Patholog Res Int. 2011. https://doi.org/10.4061/2011/167046 .
doi: 10.4061/2011/167046
pubmed: 21961078
pmcid: 3180787
Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, et al. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a “biased agonist” mechanism. Proc Natl Acad Sci U S A. 2002;99:4608–13. https://doi.org/10.1073/pnas.072077299 .
doi: 10.1073/pnas.072077299
pubmed: 11930011
pmcid: 123695
Stewart JM, Gera L, Chan DC, Bunn PA Jr, York EJ, Simkeviciene V, et al. Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol. 2002;80:275–80. https://doi.org/10.1139/y02-030 .
doi: 10.1139/y02-030
pubmed: 12025961
Stewart JM, Gera L, Chan DC, York EJ, Stewart LT, Simkeviciene V, et al. New lung cancer drugs from bradykinin antagonists. Chest. 2004;125:148S. https://doi.org/10.1378/chest.125.5_suppl.148s .
doi: 10.1378/chest.125.5_suppl.148s
pubmed: 15136471
Avdieiev S, Gera L, Havrylyuk D, Hodges RS, Lesyk R, Ribrag V, et al. Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds. Bioorg Med Chem. 2014;22:3815–23. https://doi.org/10.1016/j.bmc.2014.06.046 .
doi: 10.1016/j.bmc.2014.06.046
pubmed: 25012567
Jutras S, Bachvarova M, Keita M, Bascands JL, Mes-Masson AM, Stewart JM, et al. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells—analysis of the molecular mechanisms of its antiproliferative action. FEBS J. 2010;277:5146–60. https://doi.org/10.1111/j.1742-4658.2010.07928.x .
doi: 10.1111/j.1742-4658.2010.07928.x
pubmed: 21078129
Danilov SM, Metzger R, Klieser E, Sotlar K, Trakht IN, Garcia JGN. Tissue ACE phenotyping in lung cancer. PLoS ONE. 2019;14:e0226553. https://doi.org/10.1371/journal.pone.0226553 .
doi: 10.1371/journal.pone.0226553
pubmed: 31877149
pmcid: 6932779
Procházka J, Krepela E, Sedo A, Viklický J, Fiala P. Aminopeptidases and angiotensin I-converting enzyme activities in primary human lung tumors and lung parenchyma. Neoplasma. 1991;38:501–8.
pubmed: 1683470
Dragović T, Schraufnagel DE, Becker RP, Sekosan M, Votta-Velis EG, Erdös EG. Carboxypeptidase M activity is increased in bronchoalveolar lavage in human lung disease. Am J Respir Crit Care Med. 1995;152:760–4. https://doi.org/10.1164/ajrccm.152.2.7633739 .
doi: 10.1164/ajrccm.152.2.7633739
pubmed: 7633739
Tsakiris I, Soos G, Nemes Z, Kiss SS, Andras C, Szantó J, et al. The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas: the coexistence predicts a poor prognosis regardless of EGFR levels. J Cancer Res Clin Oncol. 2008;134:439–51. https://doi.org/10.1007/s00432-007-0304-z .
doi: 10.1007/s00432-007-0304-z
pubmed: 17922141
Denis CJ, Lambeir A-M. The potential of carboxypeptidase M as a therapeutic target in cancer. Expert Opin Ther Targets. 2013;17:265–79. https://doi.org/10.1517/14728222.2012.741122 .
doi: 10.1517/14728222.2012.741122
pubmed: 23294303
Figueroa CD, Ehrenfeld P, Bhoola KD. Kinin receptors as targets for cancer therapy. Expert Opin Ther Targets. 2012;16:299–312. https://doi.org/10.1517/14728222.2012.662957 .
doi: 10.1517/14728222.2012.662957
pubmed: 22339271
Lin KS, Pan J, Amouroux G, Turashvili G, Mesak F, Hundal-Jabal N, et al. In vivo radioimaging of bradykinin receptor B1, a widely overexpressed molecule in human cancer. Cancer Res. 2015;75:387–93. https://doi.org/10.1158/0008-5472.CAN-14-1603 .
doi: 10.1158/0008-5472.CAN-14-1603
pubmed: 25488751
Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem. 2010;391:505–11. https://doi.org/10.1515/BC.2010.056 .
doi: 10.1515/BC.2010.056
pubmed: 20302518
Lawrence MG, Lai J, Clements JA. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev. 2010;31:407–46. https://doi.org/10.1210/er.2009-0034 .
doi: 10.1210/er.2009-0034
pubmed: 20103546
Hwang YS, Cho HJ, Park ES, Lim J, Yoon HR, Kim JT, et al. KLK6/PAR1 axis promotes tumor growth and metastasis by regulating cross-talk between tumor cells and macrophages. Cells. 2022. https://doi.org/10.3390/cells11244101 .
doi: 10.3390/cells11244101
pubmed: 36611829
pmcid: 9818234
Levesque M, Yu H, D’Costa M, Tadross L, Diamandis EP. Immunoreactive prostate-specific antigen in lung tumors. J Clin Lab Anal. 1995;9:375–9. https://doi.org/10.1002/jcla.1860090607 .
doi: 10.1002/jcla.1860090607
pubmed: 8587005
Zarghami N, Levesque M, D’Costa M, Angelopoulou K, Eleftherios PD. Frequency of expression of prostate-specific antigen mRNA in lung tumors. Am J Clin Pathol. 1997;108:184–90. https://doi.org/10.1093/ajcp/108.2.184 .
doi: 10.1093/ajcp/108.2.184
pubmed: 9260759
Ding Y, Bian TT, Li QY, He JR, Guo Q, Wu CY, et al. A new risk model for CSTA, FAM83A, and MYCT1 predicts poor prognosis and is related to immune infiltration in lung squamous cell carcinoma. Am J Transl Res. 2022;14:7705–25.
pubmed: 36505278
pmcid: 9730102
Ma H, Hockla A, Mehner C, Coban M, Papo N, Radisky DC, et al. PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma. Sci Rep. 2019. https://doi.org/10.1038/s41598-018-38362-0 .
doi: 10.1038/s41598-018-38362-0
pubmed: 31892729
pmcid: 6938504
The Human Protein Atlas. 2022. https://www.proteinatlas.org/ENSG00000167754-KLK5/pathology/lung+cancer . Accessed 6 Apr 2022.
Lu J, Shi Q, Zhang L, Wu J, Lou Y, Qian J, et al. Integrated transcriptome analysis reveals KLK5 and L1CAM predict response to anlotinib in NSCLC at 3rd line. Front Oncol. 2019. https://doi.org/10.3389/fonc.2019.00886 .
doi: 10.3389/fonc.2019.00886
pubmed: 32117787
pmcid: 6933604
Koumando VL, Scorilas A. Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms. PLoS ONE. 2013;8:e68074. https://doi.org/10.1371/journal.pone.0068074 .
doi: 10.1371/journal.pone.0068074
Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22:184–204. https://doi.org/10.1210/edrv.22.2.0424 .
doi: 10.1210/edrv.22.2.0424
pubmed: 11294823
Planque C, De Monte M, Guyentant S, Rollin J, Desmazes C, Panel V, et al. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem Biophys Res Commun. 2005;329:1260–6. https://doi.org/10.1016/j.bbrc.2005.02.100 .
doi: 10.1016/j.bbrc.2005.02.100
pubmed: 15766562
Heuzé-Vourch N, Planque C, Guyetant S, Coco C, Brillet B, Blechet C, et al. High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis. J Cell Mol Med. 2009;13:4014–22. https://doi.org/10.1111/j.1582-4934.2009.00763.x .
doi: 10.1111/j.1582-4934.2009.00763.x
Sher YP, Chou CC, Chou RH, Wu HM, Chang WSW, Chen CH, et al. Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. Cancer Res. 2006;66:11763–70. https://doi.org/10.1158/0008-5472.CAN-06-3165 .
doi: 10.1158/0008-5472.CAN-06-3165
pubmed: 17178872
Planque C, Choi YH, Guyetant S, Heuzé-Vourch N, Briollais L, Courty Y. Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer. Clin Chem. 2010;56:987–97. https://doi.org/10.1373/clinchem.2009.138917 .
doi: 10.1373/clinchem.2009.138917
pubmed: 20360129
Zhang Y, Song H, Miao Y, Wang R, Chen L. Frequent transcriptional inactivation of kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci. 2010;101:934–40. https://doi.org/10.1111/j.1349-7006.2009.01486.x .
doi: 10.1111/j.1349-7006.2009.01486.x
pubmed: 20180809
Planque C, Aïnciburu M, Heuzé-Vourch N, Régina S, De Monte M, Courty Y. Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues. Biol Chem. 2006;387:783–8. https://doi.org/10.1515/BC.2006.098 .
doi: 10.1515/BC.2006.098
pubmed: 16800740
Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98:13790–5. https://doi.org/10.1073/pnas.191502998 .
doi: 10.1073/pnas.191502998
pubmed: 11707567
pmcid: 61120
Sasaki H, Kawano O, Endo K, Suzuki E, Haneda H, Yukiue H, et al. Decreased kallikrein 11 messenger RNA expression in lung cancer. Clin Lung Cancer. 2006;8:45–8. https://doi.org/10.3816/CLC.2006.n.032 .
doi: 10.3816/CLC.2006.n.032
pubmed: 16870045
Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics. 2009;8:2746–58. https://doi.org/10.1074/mcp.M900134-MCP200 .
doi: 10.1074/mcp.M900134-MCP200
pubmed: 19776420
pmcid: 2816016
Unal D, Eroglu C, Tasdemir A, Karaman H, Kurtul N, Oguz A, et al. Is human kallikrein 11 in non-small cell lung cancer treated chemoradiotherapy associated with survival? Cancer Res Treat. 2016;48:98–105. https://doi.org/10.4143/crt.2014.364 .
doi: 10.4143/crt.2014.364
pubmed: 25779361
Xu C-H, Zhang Y, Yu L-K. The diagnostic and prognostic value of serum human kallikrein-related peptidases 11 in non-small cell lung cancer. Tumor Biol. 2014;35:5199–203. https://doi.org/10.1007/s13277-014-1674-x .
doi: 10.1007/s13277-014-1674-x
Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res. 2011;17:2395–9. https://doi.org/10.1158/1078-0432.CCR-10-3024 .
doi: 10.1158/1078-0432.CCR-10-3024
pubmed: 21257721
Chou RH, Lin SC, Wen HC, Wu CW, Chang WSW. Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation. Biochem Biophys Res Commun. 2011;409:442–7. https://doi.org/10.1016/j.bbrc.2011.05.022 .
doi: 10.1016/j.bbrc.2011.05.022
pubmed: 21596022
Gueugnon F, Barascu A, Mavridis K, Petit-Courty A, Marchand-Adam S, Gissot V, et al. Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer. Tumor Biol. 2015;36:4979–86. https://doi.org/10.1007/s13277-015-3148-1 .
doi: 10.1007/s13277-015-3148-1
Planque C, Bléchet C, Ayadi-Kaddour A, Heuzé-Vourch N, Dumont P, Guyétant S, et al. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung. Biol Chem. 2008;389:781–6. https://doi.org/10.1515/BC.2008.089 .
doi: 10.1515/BC.2008.089
pubmed: 18627302
Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, et al. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res. 2008;14:1355–62. https://doi.org/10.1158/1078-0432.CCR-07-4117 .
doi: 10.1158/1078-0432.CCR-07-4117
pubmed: 18316555
Tailor PD, Kodeboyina SK, Bai S, Patel N, Sharma S, Ratnani A, et al. Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types. Oncotarget. 2018;9:17876–88. https://doi.org/10.18632/oncotarget.24947 .
doi: 10.18632/oncotarget.24947
pubmed: 29707153
pmcid: 5915161
Lizama AJ, Andrade Y, Colivoro P, Sarmiento J, Matus CE, Gonzalez CB, et al. Expression and bioregulation of the kallikrein-related peptidases family in the human neutrophil. Innate Immun. 2015;21:575–86. https://doi.org/10.1177/1753425914566083 .
doi: 10.1177/1753425914566083
pubmed: 25563717
Liew PX, Kubes P. The Neutrophil’s role during health and disease. Physiol Rev. 2019;99:1223–48. https://doi.org/10.1152/physrev.00012.2018 .
doi: 10.1152/physrev.00012.2018
pubmed: 30758246
Michel N, Heuzé-Vourch N, Lavergne E, Parent C, Jourdan ML, Vallet A, et al. Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor. Biol Chem. 2014;395:1015–25. https://doi.org/10.1515/hsz-2014-0124 .
doi: 10.1515/hsz-2014-0124
pubmed: 24643912
Lavergne M, Guillon-Munos A, Lenga MBW, Attucci S, Kryza T, Barascu A, et al. Tissue factor pathway inhibitor 2 is a potent kallikrein-related protease 12 inhibitor. Biol Chem. 2021;402:1257–68. https://doi.org/10.1515/hsz-2020-0389 .
doi: 10.1515/hsz-2020-0389
pubmed: 33977679
Guillon-Munos A, Oikonomopoulou K, Michel N, Smith CR, Petit-Courty A, Canepa S, et al. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. J Biol Chem. 2011;286:25505–18. https://doi.org/10.1074/jbc.M110.213231 .
doi: 10.1074/jbc.M110.213231
pubmed: 21628462
pmcid: 3138267
Bai Y, Zhang G, Cheng R, Yang R, Chu H. CASC15 contributes to proliferation and invasion through regulating miR-766-5p/ KLK12 axis in lung cancer. Cell Cycle. 2019;18:2323–31. https://doi.org/10.1080/15384101.2019.1646562 .
doi: 10.1080/15384101.2019.1646562
pubmed: 31378128
pmcid: 6738530
Cui Z, Sun S, Liu Q, Zhou X, Gao S, Peng P, et al. MicroRNA-378-3p/5p suppresses the migration and invasiveness of oral squamous carcinoma cells by inhibiting KLK4 expression. Biochem Cell Biol. 2020;98:154–63. https://doi.org/10.1139/bcb-2019-0017 .
doi: 10.1139/bcb-2019-0017
pubmed: 31265790